Literature DB >> 2632262

A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma.

S Longstaff1, H Sigurdsson, M O'Keeffe, S Ogston, P Preece.   

Abstract

The use of tamoxifen is expanding in its application in the treatment of breast carcinoma, and proposed prophylactic use. Tamoxifen in high dosage and in some reports at conventional dosage is associated with ocular toxicity. This study in a single blind fashion examined 79 patients receiving tamoxifen for varying treatment durations at conventional dosage and 115 patients not receiving tamoxifen. No ocular toxicity was found. Further follow up studies are required to ensure no toxicity develops in patients receiving high cumulative dosage on conventional therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2632262     DOI: 10.1016/0277-5379(89)90351-9

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  8 in total

Review 1.  Tamoxifen in the prevention of breast cancer. Are the risks likely to outweigh the benefits?

Authors:  M O'Brien; T J Powles
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 2.  Tamoxifen as adjuvant therapy in breast cancer. Current status.

Authors:  P N Plowman
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

3.  The Royal Marsden Hospital pilot tamoxifen chemoprevention trial.

Authors:  T J Powles; A L Jones; S E Ashley; M E O'Brien; V A Tidy; J Treleavan; D Cosgrove; A G Nash; N Sacks; M Baum
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Retinal function in patients treated with tamoxifen.

Authors:  Sung Eun Song Watanabe; Adriana Berezovsky; Márcia Motono; Paula Yuri Sacai; Josenilson Martins Pereira; Juliana Maria Ferraz Sallum; Luiz Henrique Gebrim; Solange Rios Salomão
Journal:  Doc Ophthalmol       Date:  2010-04       Impact factor: 2.379

Review 5.  Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

Review 6.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

Review 7.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

Review 8.  Breast cancer medications and vision: effects of treatments for early-stage disease.

Authors:  Alvin Eisner; Shiuh-Wen Luoh
Journal:  Curr Eye Res       Date:  2011-08-05       Impact factor: 2.424

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.